Tuis8AK • FRA
add
Alkermes Plc
Vorige sluiting
€26,80
Dagwisseling
€27,40 - €27,80
Jaarwisseling
€20,80 - €34,60
Markkapitalisasie
5,18 mjd USD
Gemiddelde volume
1,00
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 306,51 m | -12,52% |
Bedryfskoste | 243,52 m | -1,97% |
Netto inkomste | 22,46 m | -39,00% |
Netto winsgrens | 7,33 | -30,26% |
Wins per aandeel | 0,29 | -32,33% |
EBITDA | 21,21 m | -58,70% |
Effektiewe belastingkoers | 11,87% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 884,02 m | 18,65% |
Totale bates | 2,08 mjd | -1,97% |
Totale aanspreeklikheid | 570,39 m | -34,37% |
Totale ekwiteit | 1,51 mjd | — |
Uitstaande aandele | 164,90 m | — |
Prys om te bespreek | 2,92 | — |
Opbrengs op bates | 1,67% | — |
Opbrengs op kapitaal | 2,21% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 22,46 m | -39,00% |
Kontant van bedrywe | 98,81 m | 368,12% |
Kontant van beleggings | 9,10 m | 122,78% |
Kontant van finansiering | 747,00 k | 104,18% |
Netto kontantverandering | 108,66 m | 395,95% |
Beskikbare kontantvloei | 75,80 m | 536,44% |
Meer oor
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
Gestig
1987
Webwerf
Werknemers
1 800
